These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 16740753)
21. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. Nevalainen MT; Xie J; Torhorst J; Bubendorf L; Haas P; Kononen J; Sauter G; Rui H J Clin Oncol; 2004 Jun; 22(11):2053-60. PubMed ID: 15169792 [TBL] [Abstract][Full Text] [Related]
22. HDAC6 expression is correlated with better survival in breast cancer. Zhang Z; Yamashita H; Toyama T; Sugiura H; Omoto Y; Ando Y; Mita K; Hamaguchi M; Hayashi S; Iwase H Clin Cancer Res; 2004 Oct; 10(20):6962-8. PubMed ID: 15501975 [TBL] [Abstract][Full Text] [Related]
23. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232 [TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
25. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169 [TBL] [Abstract][Full Text] [Related]
26. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Jiang WG; Douglas-Jones AG; Mansel RE Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):125-34. PubMed ID: 16364620 [TBL] [Abstract][Full Text] [Related]
27. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Voduc D; Nielsen TO; Cheang MC; Foulkes WD Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730 [TBL] [Abstract][Full Text] [Related]
28. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784 [TBL] [Abstract][Full Text] [Related]
29. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Hara Y; Kobayashi S; Iwase H Breast Cancer Res Treat; 2005 Nov; 94(1):11-6. PubMed ID: 16172792 [TBL] [Abstract][Full Text] [Related]
30. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245 [TBL] [Abstract][Full Text] [Related]
31. WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Płuciennik E; Kusińska R; Potemski P; Kubiak R; Kordek R; Bednarek AK Eur J Surg Oncol; 2006 Mar; 32(2):153-7. PubMed ID: 16360296 [TBL] [Abstract][Full Text] [Related]
32. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978 [TBL] [Abstract][Full Text] [Related]
33. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277 [TBL] [Abstract][Full Text] [Related]
34. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653 [TBL] [Abstract][Full Text] [Related]
35. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Li R; An SJ; Chen ZH; Zhang GC; Zhu JQ; Nie Q; Xie Z; Guo AL; Mok TS; Wu YL Hum Pathol; 2008 Dec; 39(12):1792-801. PubMed ID: 18715616 [TBL] [Abstract][Full Text] [Related]
36. Aberrant expression of cyclin E in low-risk node negative breast cancer. Ahlin C; Gruhne B; Holmqvist M; Zetterberg A; Fjällskog ML Acta Oncol; 2008; 47(8):1539-45. PubMed ID: 18607847 [TBL] [Abstract][Full Text] [Related]
37. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients]. Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207 [TBL] [Abstract][Full Text] [Related]
38. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR. Koga T; Tokunaga E; Sumiyoshi Y; Oki E; Oda S; Takahashi I; Kakeji Y; Baba H; Maehara Y Hepatogastroenterology; 2008; 55(84):1131-5. PubMed ID: 18705345 [TBL] [Abstract][Full Text] [Related]
39. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Jotsuka T; Okumura Y; Nakano S; Nitta H; Sato T; Miyachi M; Suzumura K; Yamashita J Surgery; 2004 Apr; 135(4):419-26. PubMed ID: 15041966 [TBL] [Abstract][Full Text] [Related]
40. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]